Apaf1 in chronic myelogenous leukemia (CML) progression: Reduced apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis

Cell Cycle

Volumn 6, Issue 5, 2007, Pages 589-594

  Ashur Fabian, Osnat ^a   Adamsky, Konstantin ^a   Trakhtenbrot, Luba ^a   Cohen, Yoram ^a   Raanani, Pia ^a   Hardan, Izhar ^a   Nagler, Arnon ^a   Rechavi, Gideon ^a   Amariglio, Ninette ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Apaf1; Blast crisis; CML; Mutation; p53

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BCR ABL PROTEIN; PROTEIN P53;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; DNA ISOLATION; DNA SYNTHESIS; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSCRIPTION REGULATION;

EID: 33947306574     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.5.3900     Document Type: Article

References (61)

1. Hajra K, Liu J. Apoptosome dysfunction in human cancer. Apoptosis 2004; 9:691-704.
2. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-42.
3. Vogelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000; 408:307-10.
4. Vousden KH. Apoptosis. p53 and PUMA: A deadly duo. Science 2005; 309:1685-86.
5. Vogelstein B, Kinzler K. Cancer genes and the pathways they control. Nat Med 2004; 10:789-99.
6. Matapurkar A, Lazebnik Y. Requirement of cytochrome c for apoptosis in human cells. Cell Death Differ 2006.
7. Miyazaki K, Yoshida H, Sasaki M, Hara H, Kimura G, Mak T, Nomoto K. Caspase-independent cell death and mitochondrial disruptions observed in the Apaf1-deficient cells. J Biochem (Tokyo) 2001; 129:963-69.
8. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D. DNA microarray analysis of genes involved in p53 mediated apoptosis: Activation of Apaf-1. Oncogene 2001; 20:3449-55.
9. Fortin A, Cregan SP, MacLaurin JG, Kushwaha N, Hickman ES, Thompson CS, Hakim A, Albert PR, Cecconi F, Helin K, Park DS, Slack RS. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J Cell Biol 2001; 155:207-16.
10. Moroni M, Hickman E, Lazzerini DE, Caprara G, Colli E, Cecconi F, Muller H, Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol 2001; 3:552-58.
11. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5:172-83.
12. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103:4010-22.
13. Ohmine K, Ota J, Ueda M, Ueno S, Yoshida K, Yamashita Y, Kirito K, Imagawa S, Nakamura Y, Saito K, Akutsu M, Mitani K, Kano Y, Komatsu N, Ozawa K, Mano H. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene 2001; 20:8249-57.
14. Shet A, Jahagirdar B, Verfaillie C. Chronic myelogenous leukemia: Mechanisms underlying disease progression. Leukemia 2002; 16:1402-11.
15. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99:2304-09.
16. Cross N, Melo J, Feng L, Goldman J. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8:186-89.
17. Cohen N, Novikov I, Hardan I, Esa A, Brok-Simoni F, Amariglio N, Rechavi G, Ben-Bassat I, Trakhtenbrot L. Standardization criteria for the detection of BCR/ABL fusion in interphase nuclei of chronic myelogenous leukemia patients by fluorescence in situ hybridization. Cancer Genet Cytogenet 2000; 123:102-8.
18. Li L, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-31.
19. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002; 2.
20. Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I, Yeshurun M, Daniely M, Zilberstein Y, Amariglio N, Brok-Simoni F, Rechavi G, Trakhtenbrot L. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002; 16:1413-18.
21. Trakhtenbrot L, Reichart M, Shimoni A. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the DuetTM (BioView) combined morphological and cytogenetical analysis. Leukemia 2002; 16:1419-22.
22. Dumont P, Leu J, Della PAR, George D, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65.
23. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001; 22:515-17.
24. Sturm I, Bosanquet A, Radetzki S, Hummel M, Dorken B, Daniel P. Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. Int J Cancer 2006; 118:2329-36.
25. Lange T, Gunther C, Kohler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003; 101:2152-55.
26. Peller S, Yona R, Kopilova Y, Prokocimer M, Goldfinger N, Uysal A, Karabulut H, Tukun A, Bokesoy I, Tuncman G, Rotter V. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes and Cancer 1998; 21:2-7.
27. Adamson D, Thompson W, Dawson A, Bennett B, Haites N. p53 mutation and expression in lymphoma. British journal of Cancer 1995; 72:150-54.
28. Kuwahara D, Tsutsumi K, Oyake D, Ohta T, Nishikawa H, Koizuka I. Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells. Auris Nasus Larynx 2003; 30(Suppl):S85-88.
29. Soengas M, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman J, Gerald W, Lazebnik Y, Cordon-Cardo C, Lowe S. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:201-11.
30. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004; 64:2245-50.
31. Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, Hasegawa M, Yamashita J, Hayashi Y. Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. Brain Pathol 2003; 13:431-39.
32. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, Tang H, Nunez G. Dysfunctional apoptosome activation in ovarian cancer: Implications for chemoresistance. Cancer Res 2002; 62:924-31.
33. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001; 98:414-21.
34. Jia L, Patwari Y, Srinivasula S, Newland A, Fernandes-Alnemri T, Alnemri E, Kelsey S. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene 2001; 20:4817-26.
35. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A, Torres A. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004; 104:2492-98.
36. Fu W, Bertoni F, Kelsey S, McElwaine S, Cotter F, Newland A, Jia L. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003; 22:451-55.
37. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, YIshii H, Furukawa Y. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 2005; 3:325-34.
38. Rozenfeld-Granot G, Krishnamurthy J, Kannan K, Toren A, Amariglio N, Givol D, Rechavi G. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene 2002; 21:1469-76.
39. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66:5781-89.
40. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001; 61:6660-64.
41. Feinstein E, Cimino G, Gale R, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Canaani E. p53 in chronic myelogenous leukemia in acute phase. PNAS 1991; 88:6293-97.
42. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001; 15:1729-34.
43. Di Bacco A, Keeshan K, McKenna SL, Cotter TG. Molecular abnormalities in chronic myeloid leukemia: Deregulation of cell growth and apoptosis. Oncologist 2000; 5:405-15.
44. Lanza F, Bi S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 1995; 13:445-52.
45. Fioretos T, Strombeck B, Sandberg T, Johansson B, Billstrom R, Borg A, Nilsson PG, Van Den Berghe H, Hagemeijer A, Mitelman F, Hoglund M. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 1999; 94:225-32.
46. Wang Y, Hopwood VL, Hu P, Lennon A, Osterberger J, Glassman A. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia. Cancer Genetics and Cytogenetics 2004; 153:53-56.
47. Fu WN, Kelsey SM, Newland AC, Jia L. Apaf-1XL is an inactive isoform compared with Apaf-1L. Biochemical and Biophysical Research Communications 2001; 282:268-72.
48. Thijsen S, Schuurhuis G, van Oostveen J, Ossenkoppele G. Chronic myeloid leukemia from basics to bedside. Leukemia 1999; 13:1646-74.
49. Hollstein M, Sidransky D, Vogelstein B, Harris C. p53 mutations in human cancers. Science 1991; 253:49-53.
50. Mironov N, Aguelon M, Potapova G, Omori Y, Gorbunov O, Klimenkov A, Yamasaki H. Alterations of (CA)n DNA repeats and tumor suppressor genes in human gastric cancer. Cancer Res 1994; 54:41-44. 51. Karameris A, Worthy E, Gorgoulis V, Quezado M, Anastassiades O. p53 gene alterations in special types of breast carcinoma: A molecular and immunohistochemical study in archival material. J Patho 1995; 176:361-72.
51. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Borresen A, Haugen A. p53 mutations in lung tumors: Relationship to putative susceptibility markers for cancer. Cancer Res 1994; 54:1551-55.
52. van Meyel D, Ramsay D, Casson A, Keeney M, Chambers A, Cairncross J. p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J Natl Cancer Inst 1994; 86:1011-17.
53. Pellegata N, Sessa F, Renault B, Bonato M, Leone B, Solcia E, Ranzani G. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54:1556-60.
54. Mansukhani M, Osborne B, Zhong J, Matsushima A. The pattern of p53 and p21WAF1/CIP1 immunoreactivity in non-Hodgkin's lymphomas predicts p53 gene status. Diagn Mol Pathol 1997; 6:222-28.
55. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. PNAS 2003; 100:9934-39.
56. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll U. p53 has a direct apoptogenic role at the mitochondria. Moll Cell 2003; 11:577-90.
57. Ohtsuka T, Ryu H, Minamishima Y, Ryo A, Lee S. Modulation of p53 and p73 levels by cyclin G: Implication of a negative feedback regulation. Oncogene 2003; 22:1678-87.
58. Flaman J, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene 1998; 16:1369-72.
59. Cho Y, Gorina S, Jeffrey P, Pavletich N. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265:346-355.
60. Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada JI, Asaka M, Moriuchi T. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 1999; 59:4765-69.
61. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004; 89:868-69.